GSK and Vertex HIV Drug Comparable With Kaletra, Study Shows
Posted on: Thursday, 18 May 2006, 21:00 CDT
GlaxoSmithKline and Vertex Pharmaceuticals' investigational HIV drug Lexiva in combination with ritonavir was shown to be comparable to Abbott Laboratories' Kaletra in a 48-week head-to-head clinical study.
In the study, which enrolled 887 patients, 73% of patients receiving Lexiva/ritonavir maintained suppression of viral replication after 48 weeks of dosing, compared with 71% of patients receiving Kaletra.
The companies said that results will be submitted to the FDA and other health regulatory authorities when the final analysis is concluded.
Lexiva/ritonavir was compared to Kaletra in this study due to Kaletra's position as the preferred HIV protease inhibitor in treatment guidelines developed by the US Department of health and human services and the International AIDS society.
Based on these results from this study, researchers have concluded that Lexiva appears to be comparable to Kaletra and has met the primary endpoints of this non-inferiority trial.
Source: Datamonitor
Related Articles
- SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
- Results From Largest Statin Study of Patients With Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease
- Results of Sepracor's LUNESTA(R) Next-Day Driving Study in Patients With Primary Insomnia Presented at American College of Neuropsychopharmacology Meeting
- ZymoGenetics Releases Preliminary Findings From Atacicept (TACI-Ig) Phase 1b Studies in Patients With Lupus
- Web Seminar Offered -- ''EHR Case Study: Delivering Patient Data Today''
- ZymoGenetics Reports Preliminary Positive Results From TACI-Ig Phase 1b Study in Patients With Rheumatoid Arthritis
- New Study Suggests Patients With Schizophrenia Improved With Treatment Change to RISPERDAL(R) CONSTA(R)
- Long-Term Safety Data Of LEXIVA/R In HIV Patients Co-Infected With Hepatitis
- IL-1 Trap Shows Positive Results in Study of Patients With Inflammatory Disease
- Evidence That HIV Protease Inhibitor, LEXIVA Plus Ritonavir (RTV) May Replace AGENERASE + RTV Without Pharmacokinetic Impact Presented at ICAAC
 |
 |
User Comments (0)
RSS Feeds